Henry Schein Inc. (NASDAQ:HSIC) – Northcoast Research boosted their Q2 2017 earnings per share estimates for Henry Schein in a research note issued on Tuesday. Northcoast Research analyst E. Snyder now expects that the brokerage will earn $1.78 per share for the quarter, up from their previous estimate of $1.77. Northcoast Research also issued estimates for Henry Schein’s Q3 2017 earnings at $1.85 EPS, Q4 2017 earnings at $2.06 EPS and FY2017 earnings at $7.28 EPS.
HSIC has been the topic of several other research reports. Zacks Investment Research lowered shares of Henry Schein from a “hold” rating to a “sell” rating in a research note on Tuesday, September 20th. Bank of America Corp. initiated coverage on shares of Henry Schein in a research note on Monday, September 12th. They set a “buy” rating and a $185.00 price objective on the stock. Finally, Credit Suisse Group AG reaffirmed a “hold” rating on shares of Henry Schein in a research note on Saturday, June 4th. One analyst has rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $157.84.
Shares of Henry Schein (NASDAQ:HSIC) traded up 1.14% on Thursday, hitting $162.98. 541,252 shares of the stock traded hands. The firm has a market capitalization of $13.33 billion, a PE ratio of 27.61 and a beta of 1.03. Henry Schein has a 52 week low of $134.75 and a 52 week high of $183.00. The firm’s 50 day moving average is $162.83 and its 200 day moving average is $170.65.
Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Thursday, August 4th. The company reported $1.64 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.63 by $0.01. Henry Schein had a net margin of 4.42% and a return on equity of 17.84%. The company had revenue of $2.87 billion for the quarter, compared to analyst estimates of $2.85 billion. During the same quarter in the prior year, the business posted $1.46 EPS. Henry Schein’s quarterly revenue was up 9.3% on a year-over-year basis.
A number of institutional investors have recently modified their holdings of HSIC. Vanguard Group Inc. increased its position in shares of Henry Schein by 2.2% in the second quarter. Vanguard Group Inc. now owns 7,493,463 shares of the company’s stock worth $1,324,844,000 after buying an additional 161,065 shares during the last quarter. BlackRock Fund Advisors increased its position in shares of Henry Schein by 2.4% in the second quarter. BlackRock Fund Advisors now owns 2,369,132 shares of the company’s stock worth $418,863,000 after buying an additional 55,384 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its position in shares of Henry Schein by 0.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 2,342,943 shares of the company’s stock worth $404,462,000 after buying an additional 8,593 shares during the last quarter. Janus Capital Management LLC increased its position in shares of Henry Schein by 16.5% in the second quarter. Janus Capital Management LLC now owns 2,027,848 shares of the company’s stock worth $358,522,000 after buying an additional 286,929 shares during the last quarter. Finally, UBS Asset Management Americas Inc. increased its position in shares of Henry Schein by 55.7% in the second quarter. UBS Asset Management Americas Inc. now owns 802,401 shares of the company’s stock worth $141,865,000 after buying an additional 286,976 shares during the last quarter. Institutional investors and hedge funds own 91.98% of the company’s stock.
In other news, Director Paul Brons sold 3,381 shares of the business’s stock in a transaction on Monday, August 29th. The shares were sold at an average price of $164.03, for a total value of $554,585.43. Following the sale, the director now owns 13,715 shares of the company’s stock, valued at $2,249,671.45. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 1.27% of the stock is currently owned by insiders.
About Henry Schein
Henry Schein, Inc is a provider of health care products and services to office-based dental, animal health and medical practitioners. The Company’s segments include healthcare distribution, and technology and value-added services. The healthcare distribution segment aggregates its global dental, animal health and medical operating segments.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.